INCY Stock Incyte Corporation
BUY US · NasdaqGSValuation looks reasonable for a cash-generative biotech with near-term pipeline catalysts.
Future value: $129.54 (+14.33%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Defensive biotech cash flow with catalysts ahead.
- ▾Below 50-day MA (-6.45%)
- ▸Above 200-day MA — long-term uptrend
Is INCY a buy right now?
Trend: INCY is trading below the 50-day average (-6.46%), RSI 27 — oversold territory, with a 3-month return of -12.79%.
Valuation & quality: Incyte Corporation trades on a trailing P/E of 14.4, forward P/E 13.1, PEG 10.82, price-to-book 3.59; fundamentals show net margin 27.7%, return on equity 30.7%, revenue growth 37.7% year on year.
Analyst consensus: 24 analysts have a mean 12-month price target of $129.54 (+14.3% vs the last close; range $86.00 – $157.00), consensus rating “buy”.
Our screen: BUY (score 2) — Valuation looks reasonable for a cash-generative biotech with near-term pipeline catalysts.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -7.10% | +1.20% | +1.50% | +17.20% | +5.40% | +3.10% | -1.50% | -6.60% |
Fundamentals
Analyst price target
Technical signals
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Sector: Healthcare · Industry: Biotechnology · United States · 2,844 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.